Indonesia vs. Singapore, Vietnam and Thailand: Where Should Life Sciences Investors Build Their Southeast Asian Base?

Everything we have published on Indonesia so far has looked at the country on its own terms. No serious investor evaluates a market that way. This article puts Indonesia's scale, biodiversity and emerging ecosystem — documented across our sector map and the biodiversity analysis that followed it — directly beside the three markets it is actually competing against for the same capital.

Four Countries, Four Different Bets

Southeast Asia does not offer investors one life sciences opportunity — it offers at least four, and they are not interchangeable. Singapore sells regulatory certainty and capital depth to companies that already have a product. Vietnam sells manufacturing cost advantages to companies chasing margin. Thailand sells a mature clinical and hospital system to companies that need patients and trial sites now. Indonesia sells something none of the other three can: a market large enough to matter on its own, and a biological resource base none of its neighbors come close to matching.

The honest version of this comparison does not crown a winner. It sorts investors by what they are actually trying to do, and shows which country fits which mandate. A biologics manufacturer chasing WHO-grade regulatory certainty has little reason to start in Jakarta over Singapore. A cosmeceuticals company hunting for novel, patentable natural ingredients has little reason to start in Singapore over Jakarta. Both can be true at once, and this article works through why.

Regional Snapshot

Figures drawn from IMF World Economic Outlook data (via Wikipedia's compiled ASEAN GDP listing), the Lowy Institute Asia Power Index, and the national industry sources cited at the end of this article.

Singapore: The Hub You Rent, Not the Market You Build In

Singapore's pitch has nothing to do with its own population of 5.9 million, too small to be a meaningful demand market. The pitch is regulatory trust and capital concentration. Its Health Sciences Authority became the first national medicines regulator to receive the World Health Organization's highest recognition for an advanced regulatory system — a credential that lets a product approved in Singapore move more smoothly through other jurisdictions that recognize that standard.

Behind that credibility sits real money. Singapore committed roughly US$3.1 billion to life sciences R&D in its 2025 budget alone, close to 3% of total government expenditure, and its five-year Research, Innovation and Enterprise 2030 plan carries a S$37 billion commitment with health and biomedical sciences as a named priority. Its biotech company count has grown roughly fivefold since 2015, to more than 60, and biopharmaceutical manufacturing alone generates close to US$38 billion in annual output — 2.6% of GDP.

None of that makes Singapore a place to sell into. It makes Singapore a place to headquarter from, manufacture high-value biologics in, or use to unlock trust with global regulators before entering larger, messier markets — including Indonesia's.

Vietnam: Manufacturing Momentum, Pharma Capital Still Catching Up

Vietnam's story is speed and cost. Total foreign direct investment reached US$27.6 billion in 2025, up 9% year-on-year and a five-year high, with manufacturing absorbing 82.8% of that total. Its 2024 Pharmaceutical Law amendment now allows up to 100% foreign ownership of pharmaceutical manufacturing facilities, and the government targets meeting 80% of domestic drug demand through local production by 2030.

Pharma-specific investment hasn't caught up to that broader momentum. Only around 150 foreign enterprises have invested in Vietnam's pharmaceutical sector, with cumulative capital of roughly US$1.8 billion — small against a pharmaceutical market already worth approximately US$7 billion. Vietnam still imports more than 60% of its active pharmaceutical ingredients, and R&D spending sits at roughly 0.4% of GDP, though national strategy targets 1.5% by 2030.

The combination — real policy liberalization, a low cost base, and a pharma sector foreign capital has largely not yet found — is what makes Vietnam interesting: a manufacturing and cost-arbitrage opportunity more than a research or biodiversity one, currently underpenetrated relative to its own market size.

Thailand: The Region's Most Mature Healthcare System

Thailand's advantage is maturity, not scale or novelty. It has run formal, WHO-aligned biosimilar approval guidelines since 2013 — over a decade longer than Indonesia's advanced-therapy framework — and that track record shows up in 62 Joint Commission International-accredited hospitals, the fourth-highest count outside the United States, and roughly 3.5 million medical tourists a year generating close to US$600 million in visitor spending.

The government's Medical Hub 2025–2034 strategy formalizes this advantage across five pillars, backed by Board of Investment incentives offering biotechnology developers up to ten years of uncapped corporate income tax exemption. Thailand's most advanced biologics manufacturer, Siam Bioscience, anchors a domestic pharmaceutical market of roughly US$6.9 billion — the third-largest in Southeast Asia.

The soft spot is research intensity: Thailand's gross R&D expenditure actually declined from 1.16% of GDP in 2022 to 0.94% in 2023, driven by a pullback in private-sector investment, before a modest projected recovery. Thailand's strength is proven clinical and regulatory execution, not an accelerating research base — the opposite trajectory from Indonesia's, where spending is lower in absolute terms but currently rising rather than falling.

Indonesia: Where Scale, Demand and Biodiversity Meet an Ecosystem Still Being Built

Set against these three neighbors, Indonesia does not win on every measure. Its research spending, at roughly 0.3% of GDP, is the lowest of the four. Its regulatory framework for advanced therapies and biologics, built out substantially only in 2025, is by a decade the youngest. Its API supply chain, importing 85% of core inputs, is more import-dependent than Vietnam's. None of that is new to readers of our earlier work — our earlier analyses documented each gap directly.

What Indonesia offers instead is scale and a resource base none of the other three can replicate at any price. A population of 285.7 million makes its domestic demand larger than Singapore, Thailand and Vietnam combined, and its US$11 billion pharmaceutical market is already the largest in ASEAN — a current fact, not a projection. Layered onto that is the biodiversity advantage documented in our biodiversity analysis: Indonesia already generates the largest share of Southeast Asia's marine natural products research, and its own regulator has quantified a traditional-medicine opportunity of Rp350 trillion against barely 1% currently realized.

The more precise way to state Indonesia's position: Singapore, Thailand and Vietnam are each optimized for a narrower purpose — regulatory trust, clinical execution, manufacturing cost — and have largely captured the value available within that purpose already. Indonesia is not yet optimized for any single purpose, which is exactly why our earlier articles found so many unresolved gaps — and exactly what leaves room for early capital to shape outcomes rather than simply rent space in an already-settled market.

Side by Side

The table below compresses the argument of this article into a single reference. It is deliberately qualitative in places — regulatory maturity and cost base do not reduce cleanly to one number — but every entry is grounded in the data discussed above.

Qualitative characterizations (regulatory maturity, cost base) reflect SciencePreneur's assessment based on the sourced figures discussed in this article, not a formal index.

What This Means for Investors

No other Southeast Asian market combines Indonesia's current pharmaceutical market size, population scale and biodiversity research output — but that combination arrives alongside the least mature regulatory and research infrastructure of the four countries compared here. Indonesia's trajectory is currently rising, while Thailand's research intensity is falling and Singapore and Vietnam are optimizing narrower advantages rather than expanding into new ones:

• Competitive positioning: an investor is rarely choosing Indonesia instead of Singapore, Thailand or Vietnam; more often the realistic choice is Indonesia for market access and biological assets, paired with one of the other three for regulatory anchoring, clinical execution or manufacturing cost.
• Barrier: Indonesia's R&D intensity and API self-sufficiency genuinely lag all three peers — real, quantified gaps, not framing problems.
• Investment gap: the same gaps that make Indonesia the least mature market of the four — thin R&D funding, a young regulatory framework, import-dependent manufacturing — are precisely where capital entering now can shape outcomes rather than compete for space in an already-settled market.
• Entry models: a Singapore holding or manufacturing structure paired with Indonesian market access; Vietnam-style manufacturing joint ventures adapted to Indonesia's own API-localization push; or direct entry built around Indonesia's unmatched biodiversity and demand base, accepting a higher execution burden for a market with no regional substitute.

Choosing the Right Base, Not Just the Right Country

The most useful thing this comparison can do is discourage a false choice. Few investors need to pick one Southeast Asian country and commit fully to it; most need a structure that uses each market for what it does best. A company might manufacture a biologic in Singapore under HSA oversight, run early clinical work in Thailand's hospital network, source cost-efficient finished-dose production in Vietnam, and sell into Indonesia's 285-million-person market while sourcing novel actives from its biodiversity — all inside one regional strategy.

SciencePreneur's role sits specifically at the Indonesia end of that structure: helping investors who have already decided Indonesia belongs in their regional footprint navigate the market-entry, regulatory and partnership questions we have mapped in detail — a narrower and more honest role than claiming Indonesia should replace Singapore, Thailand or Vietnam, which for most companies it should not.

Where This Leaves the Investor

This article has not argued that Indonesia is the best Southeast Asian market for life sciences investment. It has argued something narrower and more defensible: Indonesia is the only regional market offering this specific combination of population scale, current pharmaceutical market size and unmatched biodiversity — worth serious consideration precisely because it cannot be found anywhere else in the region, not because Indonesia outperforms its neighbors on every measure, because it plainly does not.